Home › NDC Lookup › RxCUI directory › RxCUI 1869816

Oxymetazoline hydrochloride 10 MG/ML Topical Cream — RxCUI 1869816

RxNorm drug concept · Semantic clinical drug
RxCUI 1869816 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1869816
Official nameOxymetazoline hydrochloride 10 MG/ML Topical Cream
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asoxymetazoline HCl 1 % Topical Cream
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)2,766 prescriptions · 17 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Oxymetazoline Nasal Spray: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Oxymetazoline nasal spray works quickly to shrink swollen nasal membranes and relieve congestion. Each dose is meant to last 10 to 12 hours, which is why you use it no more than tw...
  • How fast does oxymetazoline nasal spray work, and how long does it last?
  • Using oxymetazoline nasal spray for more than 3 days in a row can trigger something called rebound congestion — where your nose gets stuffy again, sometimes worse than before, as s...
  • Yes, a mild burning, stinging, or sneezing sensation right after using the spray is a known side effect and is usually nothing to worry about. Some people also notice a brief incre...
📖 Read our full Oxymetazoline Nasal Spray guide →

🕸️ Concept Web — How Oxymetazoline hydrochloride 10 MG/ML Topical Cre... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Oxymetazoline hydrochloride 10 MG/ML Topical Cream RxCUI 1869816

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Oxymetazoline 7812
    • Oxymetazoline hydrochloride 106101
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rhofade 1869817
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Oxymetazoline Topical Cream 1869815
    • Oxymetazoline hydrochloride Topical Cream 2649124
    • Oxymetazoline Topical Product 1869814
    • Oxymetazoline hydrochloride Topical Product 2660935
    • Oxymetazoline Topical Cream [Rhofade] 1869819
    • Oxymetazoline hydrochloride Topical Cream [Rhofade] 2658653
    • Rhofade Topical Product 1869820
    • Topical Cream 316982
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Oxymetazoline hydrochloride 10 MG/ML SCDC · 1869813
  • Oxymetazoline Topical Cream SCDF · 1869815
  • Oxymetazoline hydrochloride Topical Cream SCDFP · 2649124
  • Oxymetazoline Topical Product SCDG · 1869814
  • Oxymetazoline hydrochloride Topical Product SCDGP · 2660935

Brand-Name Concepts

  • Oxymetazoline hydrochloride 10 MG/ML Topical Cream [Rhofade] SBD · 1869821
  • Oxymetazoline hydrochloride 10 MG/ML [Rhofade] SBDC · 1869818
  • Oxymetazoline Topical Cream [Rhofade] SBDF · 1869819
  • Oxymetazoline hydrochloride Topical Cream [Rhofade] SBDFP · 2658653
  • Rhofade Topical Product SBDG · 1869820
  • Rhofade BN · 1869817

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 1869816 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
51862-0765-00 15 TUBE in 1 CARTON (51862-765-00) / 3 g in 1 TUBE Rhofade Mayne Pharma 2025-07-11
51862-0765-30 1 TUBE in 1 CARTON (51862-765-30) / 30 g in 1 TUBE Rhofade Mayne Pharma 2024-10-24
71403-0003-15 1 TUBE in 1 CARTON (71403-003-15) / 3 g in 1 TUBE Rhofade EPI Health, LLC 2021-01-18
71403-0003-30 1 TUBE in 1 CARTON (71403-003-30) / 30 g in 1 TUBE Rhofade EPI Health, LLC 2021-01-18
Observed labelers: EPI Health, LLC (2) · Mayne Pharma (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.